Trial · NCT03809429
Outcomes27
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Oocytes Retrieved | On day of oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Oocytes | MEAN |
| SECONDARY | Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response | At end-of-stimulation (up to 20 days) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | participants | NUMBER |
| SECONDARY | Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | At end of transfer (up to 4 weeks) | Participants analyzed for this endpoint represent participants with blastocyst transfer cancellation. | participants | NUMBER |
| SECONDARY | Number of Follicles | On stimulation day 6 and at end-of-stimulation (up to 20 days) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Number of follicles | MEAN |
| SECONDARY | Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved | On day of oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Metaphase II Oocytes | On day of oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | MII oocytes | MEAN |
| SECONDARY | Fertilization Rate | On day 1 after oocyte retrieval (up to 23 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | percentage of fertilized oocytes | MEAN |
| SECONDARY | Number of Embryos | On day 3 after oocyte retrieval (up to 25 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Embryos | MEAN |
| SECONDARY | Number of Blastocysts | On day 5 after oocyte retrieval (up to 27 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Blastocysts | MEAN |
| SECONDARY | Circulating Concentrations of Follicle-stimulating Hormone (FSH) | On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | IU/L | MEAN |
| SECONDARY | Circulating Concentrations of Luteinizing Hormone (LH) | On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | IU/L | MEAN |
| SECONDARY | Circulating Concentrations of Estradiol | On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | pmol/L | MEAN |
| SECONDARY | Circulating Concentrations of Progesterone | On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | nmol/L | MEAN |
| SECONDARY | Circulating Concentrations of Inhibin B | On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | pg/mL | MEAN |
| SECONDARY | Total Gonadotropin Dose | Up to 20 days | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | ug | MEAN |
| SECONDARY | Number of Stimulation Days | Up to 20 days | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Days | MEAN |
| SECONDARY | Positive Beta Human Chorionic Gonadotropin (βhCG) Rate | 13-15 days after transfer (up to approximately 1.5 months after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Implantation Rate | 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Embryos | NUMBER |
| SECONDARY | Clinical Pregnancy Rate | 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Vital Pregnancy Rate | 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation) | Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03809429/outcomes